Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) EPS (Weighted Average and Diluted) (2019 - 2025)

Entera Bio has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at $0.07 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 16.67% year-over-year to $0.07, compared with a TTM value of $0.26 through Dec 2025, up 4.0%, and an annual FY2025 reading of $0.25, changed 0.0% over the prior year.
  • EPS (Weighted Average and Diluted) came in at $0.07 for Q4 2025, roughly flat from $0.07 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.15 in Q4 2021 to a low of -$0.11 in Q2 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.08 (2023), compared with a mean of $0.07.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 164.84% in 2021, then skyrocketed 199.79% in 2022.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.15 in 2021, then plummeted by 33.33% to $0.1 in 2022, then crashed by 30.0% to $0.07 in 2023, then dropped by 14.29% to $0.06 in 2024, then increased by 16.67% to $0.07 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's EPS (Weighted Average and Diluted) are $0.07 (Q4 2025), $0.07 (Q3 2025), and $0.06 (Q2 2025).